NRG-GY005/COCOS: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or p

Protocol: 
AAAR3339
Phase: 
II/III

NRG-GY005/COCOS: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or p

Are you Eligible? (Inclusion Criteria)

1. Histologically or cytologically confirmed ovarian cancer, peritoneal cancer
or fallopian tube cancer and must have a histological diagnosis of either serous
or endometrioid cancer based on local histopathological findings. Both
endometrioid and serous histology should be high-grade for eligibility of non-
mutation carriers. Patients with clear cell, mixed epithelial, undifferentiated
carcinoma, or transitional cell carcinoma histologies are also eligible,
provided that the patient has a known deleterious germline BRCA1 or BRCA2
mutation identified through testing at a clinical laboratory.
2. Patients should have disease that has progressed by imaging while receiving
platinum or had recurrence within 6 months of the last receipt of platinum-based
chemotherapy
3. No more than 3 prior treatment regimens (including primary therapy; no more
than 1 prior non-platinum based therapy in the platinum-resistant/-refractory
setting).

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States